Recent Quotes (30 days)

You have no recent quotes
chg | %

Mirati Therapeutics Inc  

(Public, TSE:MYG)   Watch this stock  
0.0000
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.50 - 22.00
Open     -
Vol / Avg. 0.00/963.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -2.95
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -90.65% -89.17%
Return on average equity -100.70% -162.00%
Employees 33 -
CDP Score - -

Address

9393 Towne Centre Dr Ste 200
SAN DIEGO, CA 92121-3070
United States - Map
+1-858-3323410 (Phone)
+1-888-2115624 (Fax)

Website links

Description

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company focuses its development programs on drugs intended to treat specific subsets of cancer patients with unmet needs. Its pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, multi-targeted kinase inhibitors with distinct target profiles that are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. The Company’s MGCD265 is an orally-bioavailable, potent, small molecule multi-targeted kinase inhibitor of Met, Axl and VEGFRs. MGCD516 is an orally-bioavailable, potent, small molecule multi-targeted kinase inhibitor of RET, TRK, DDR and EphRs, as well as Met, Axl and VEGFRs, in development for the treatment of solid tumors. Mocetinostat is an orally-bioavailable, spectrum-selective HDAC inhibitor.

Officers and directors

Rodney W. Lappe Ph.D. Independent Chairman of the Board
Age: 60
Charles M. Baum M.D., Ph.D. President, Chief Executive Officer, Director
Age: 56
Mark J. Gergen J.D. Chief Operating Officer, Executive Vice President
Age: 52
Isan Chen M.D. Chief Medical and Development Officer, Executive Vice President
Age: 52
James Christensen Senior Vice President, Chief Scientific Officer
Age: 46
Jamie A. Donadio Vice President - Finance
Age: 39
Michael G. Grey Director
Age: 62
Henry J. Fuchs M.D.,Ph.D. Independent Director
Age: 57
Craig A. Johnson Independent Director
Age: 53
William R. Ringo Independent Director
Age: 69